Completed PHASE3 INTERVENTIONAL NCT00563225

20 Week Bridging Study in Type II DM

A Multicenter, Non-Comparative, Open, Phase III Study to Evaluate the Efficacy and Safety of Insulin Glargine on Subjects With Type 2 Diabetes Mellitus

Sponsor: Sanofi

Conditions Diabetes Mellitus Type II

Interventions Insulin Glargine

Updated 5 times since 2017 Last updated: Nov 23, 2007 Started: Oct 31, 2002 Completion: Apr 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00563225, this PHASE3 trial focuses on Diabetes Mellitus Type II and remains completed. Sponsored by Sanofi, it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.